All Articles
PIK3CA testing adoption readiness for breast cancer in 9 European countries

PIK3CA testing adoption readiness for breast cancer in 9 European countries

18 December, 2020


PIK3CA represents a new molecular biomarker for HR+ HER2- BRCA‒advanced breast cancer in postmenopausal patients. In May 2019, the FDA approved the first PIK3 inhibitor for breast cancer patients with a Real Time (RT)-PCR‒based companion diagnostic (CDx) that can be used for both tissue and plasma samples.

Current breast cancer guidelines recommend molecular testing to be performed on specific request of the physician or in cases of hereditary breast cancer. To determine real-world laboratory readiness for PIK3CA adoption, we investigated the current use of molecular testing methodologies in 111 laboratories from 9 European countries.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny